Breaking News

GentiBio, Forge Biologics Ink Development and Manufacturing Agreement

Partnership to support GentiBio’s cell therapy pipeline with AAV process development, scale up and GMP manufacturing services.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GentiBio, an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, and Forge Biologics, a cell and gene therapy-focused contract development and manufacturing organization (CDMO), have entered a development and manufacturing partnership to advance GentiBio’s immune tolerance platform.   Forge will provide adeno-associated viral (AAV) vector process and analytical development, sc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters